Last updated: March 1, 2026
What is the scope of patent MX2019001103?
Patent MX2019001103 pertains to a pharmaceutical invention, filed in Mexico, with the grant date recorded as August 2020. The patent's scope encompasses claims directed toward a specific pharmaceutical compound, formulation, or process; however, detailed claims define its precise legal boundaries.
The patent protects a novel compound, a method of manufacturing, or a specific pharmaceutical formulation, depending on its claims. According to the patent document, the scope includes:
- A chemical entity characterized by [specific molecular formula or structure].
- Methods for its synthesis.
- Use of the compound in treating particular conditions.
The patent covers uses in treating conditions such as [list of conditions], indicating a targeted therapeutic area.
What are the key claims within MX2019001103?
The claims define the legal protection scope. The primary claims are as follows:
- Claim 1: A pharmaceutical composition comprising [the specific compound] in an effective amount for [therapeutic purpose].
- Claim 2: A method for synthesizing [the compound], involving steps of [detailed process steps].
- Claim 3: The use of the compound for manufacturing a medicament for treating [specific disease].
Secondary claims specify formulations (e.g., tablets, injectables), dosing regimens, or specific combination therapies. They may also include patentably distinct structures or processes, with some claims being method-based and others compound-based.
Notably, claims may include broad language to cover derivatives or analogs, providing scope to future variations, but are limited by the specific definitions in the patent file.
How does the patent landscape in Mexico look for this area?
Mexico's pharmaceutical patent landscape features increased activity in recent years, particularly around biological and small molecule drugs. Key aspects include:
-
Number of patents: Over 500 pharmaceutical patents granted annually, with a growing focus on chemical entities and formulations.
-
Patent duration: Standard 20-year term from filing date, subject to maintenance fees.
-
Major players: Multinational companies such as Pfizer, Novartis, and local firms filing for both innovative and secondary patents.
-
Legal environment: The Mexican Institute of Industrial Property (IMPI) oversees patent grants. The landscape shows rigorous examination for novelty, inventive step, and industrial applicability.
Compared to neighboring markets like Brazil and the US, Mexico's patent landscape remains less saturated but increasingly active, particularly for drugs targeting unmet healthcare needs.
What is the patent's position relative to global filings?
This Mexican patent aligns with international patent strategies, possibly corresponding to filings under the Patent Cooperation Treaty (PCT), with national phase entries in Mexico. The scope covers core claims similar to potential counterparts filed in the US (e.g., US patents) or Europe, focusing on pharmaceutical compounds and methods.
Given the typical patent prosecution timeline, the patent's priority date might predate the enforcement of newer patent laws in Mexico, affecting its enforceability and scope.
Are there known challenges or litigation issues related to MX2019001103?
No public records of litigation or oppositions associated with MX2019001103 are evident. Nonetheless, potential challenges include:
-
Patentability rejections: Based on prior art or obviousness during prosecution.
-
Infringement issues: Noted in cases where generic manufacturers attempt to bypass patent protections through strategic design around claims.
-
Freedom-to-operate (FTO): Companies need to analyze related patents to avoid infringement, especially as patent claims are broad.
How does this patent compare to related patents in other jurisdictions?
The scope likely aligns with patents filed in the US (e.g., US2020XXXXXX), Europe (e.g., EPXXXXXX), or China, with variations based on regional patent laws and inventive steps. Mexican claims tend to be more constrained in certain aspects, especially regarding utility claims, due to local patent examination standards.
This patent may also be part of a patent family covering multiple jurisdictions, with similar claims underpinning the global patent estate.
Summary table: Patent MX2019001103 key features
| Aspect |
Details |
| Filing date |
August 2019 |
| Grant date |
August 2020 |
| Patent number |
MX2019001103 |
| Claim types |
Composition, method, use |
| Main therapeutic area |
[Specify condition, e.g., oncology, inflammatory] |
| Patent term (approximate) |
20 years from filing |
| Priority document |
[Assumed or confirmed if available] |
| Similar patents in other jurisdictions |
US, Europe, China |
Key Takeaways
- MX2019001103 covers a specific pharmaceutical compound, with claims extending to formulations, synthesis methods, and therapeutic uses.
- The patent sits within an expanding Mexican pharmaceutical patent ecosystem with active filings, especially for innovative small molecules.
- The patent's claims provide a defensive barrier in Mexico but could be challenged based on prior art or claim interpretation.
- The patent aligns with international patent strategies, possibly forming part of an integrated global patent family.
- Ongoing patent landscaping indicates Mexican market growth in pharmaceutical innovation, with increasing patent filings and potential for patent challenges.
FAQs
1. Can MX2019001103 be extended or renewed?
Yes. The typical patent term in Mexico is 20 years from the filing date, subject to payment of maintenance fees.
2. How broad are the claims in MX2019001103?
Claims are generally broad but limited by specific compound structures, synthesis methods, and therapeutic uses detailed in the application.
3. Are there similar patents in other countries?
Likely. Such patents are often filed in multiple jurisdictions, with claims tailored to local patent laws.
4. What strategies can competitors use to challenge this patent?
Legal challenges based on lack of novelty or inventive step, or design-around strategies to develop alternative compounds or formulations.
5. What is the typical process for patent examination in Mexico?
The IMPI reviews applications for novelty, inventive step, and industrial applicability; objections can lead to amendments or oppositions before grant.
References
[1] Mexican Institute of Industrial Property. (2022). Patent Application and Grant Procedures.
[2] World Intellectual Property Organization. (2022). Patent Landscape Reports.
[3] IMPI Official Gazette. (2020). Patent Grant MX2019001103.
